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patients
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Abstract 
Background: Longer treatment duration is important for the successful treatment of gambling disorder (GD). This 
retrospective study investigated the factors and interventions that might enhance treatment duration in GD patients 
in South Korea.
Methods: A total of 758 outpatients with a primary diagnosis of GD, who were treated in a clinical practice from 2002 
to 2011, were assessed by retrospective chart review. We compared the treatment duration according to pharmaco‑
therapy and group cognitive behavioral therapy (CBT).
Results: Pharmacotherapy contributed to a longer duration of treatment maintenance, despite the patients’ gam‑
bling severity (p < 0.001). Participation in group CBT (p < 0.001) and antidepressants (p = 0.009) were associated with 
a longer treatment duration after adjusting for age, depression, and gambling severity. The treatment maintenance 
duration was the longest in those receiving combined antidepressant pharmacotherapy and group CBT (F = 35.79, 
p < 0.001).
Conclusions: Group CBT and antidepressants seem to enhance treatment follow‑up duration in GD patients. Addi‑
tional studies are needed to advance GD prevention and treatment strategies.
Keywords: Gambling disorder, Treatment duration, Group cognitive behavioral therapy (CBT), Pharmacotherapy, 
Individual psychotherapy
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Background
Gambling disorder (GD), or pathological gambling, has 
rarely been studied as a disease. Until the late 1990s, lit-
tle was known about the history and etiology of GD [1]. 
Recently, GD was classified as a clinically significant 
addictive disorder [2]. Although GD affects 0.2–5.3 % of 
adults and often results in severe damage to the lives of 
patients and their families, less than 10 % of those with 
GD receive professional treatment [3].
Cognitive behavioral therapy (CBT), 12-step programs, 
and pharmacological approaches have been proven to be 
effective treatments for GD [4]. The relative efficacy of 
medications remains a topic of ongoing research, as GD 
has only recently been recognized as a biological disease 
[5]. In recent years, several controlled clinical trials have 
been conducted on a variety of pharmaceutical classes 
and have established an evidence-based background for 
the disease [6]. However, the influence of these treatment 
modalities on treatment duration and adherence in GD 
has rarely been studied, and has not yet been revealed [7].
GD has been characterized as a chronic relapsing dis-
order with high treatment dropout rates, ranging from 
43 to 80 % according to the study design including treat-
ment duration and modalities [8]. One study reported 
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an 18-month treatment duration; however, this study 
included only the participants who remained in treat-
ment for a minimum of 60 days [9]. Thus, motivation and 
adherence to treatment are the most important factors 
in the successful treatment of GD [10, 11]. The majority 
of pathological gamblers do not seek treatment although 
they have serious psychosocial problems. Rather, family 
members pressure the affected relative to start and con-
tinue therapy [12]. Patients with addictive disorders often 
discontinue treatment before remission or recovery. 
Although dropout is an important factor in the outcomes 
of managing mental health problems [13], the clinical 
characteristics or interventions that might enhance the 
duration of treatment maintenance have not yet been 
revealed.
The current study investigated whether treatment 
intervention, and which treatment approach, is related to 
a lower rate of dropout in GD patients in South Korea.
Methods
Participants
The study participants were adults, aged 18–65  years, 
who visited the gambling clinic in Kangbuk Sam-
sung Hospital between May 2002 and December 2011. 
From February 2012 to March 2013, we retrospectively 
reviewed the medical charts of these patients with GD.
Using the Structured Clinical Interview for the Diag-
nostic and Statistical Manual of Mental Disorders, 4th 
Edition (DSM-IV) for Axis I disorders (SCID-I), a tool for 
diagnosing GD and identifying psychiatric comorbidities 
[14], a psychiatrist (Y.C. Shin, one of the co-first authors) 
diagnosed all of the patients with GD. We enrolled sub-
jects who scored at least 5 on the Korean version of the 
South Oaks Gambling Screen (K-SOGS) [15].
There were 23, of the initial 824, cases that were 
excluded from the study because the family members 
sought counseling in lieu of the person who gambled. 
According to the exclusion criteria, additionally 11 par-
ticipants were excluded due to lifetime diagnosis of a 
psychotic disorder, mental retardation, and substance 
use disorder, except for alcohol and nicotine dependence. 
None of the participants were provided with a thera-
pist’s recommendation to discontinue treatment due to 
improvement, given that “improvement” is regarded as 
temporary in GD, and all of the patients were advised to 
continue treatment throughout their lifetime. However, 
an additional 32 patients were excluded from the current 
study because they terminated treatment in this outpa-
tient GD clinic upon agreement with a therapist. Of these 
patients, 20 were referred to gamblers anonymous (GA) 
or other outpatient clinics due to the far travel distance 
to the study clinic. The remaining 12 of the 32 patients 
who terminated treatment at the clinic were referred to 
inpatient clinics, or other institutes, because of severe 
recurrence including the increase of debt or gambling 
severity. Finally, a total of 758 participants were included 
in this study. The study protocol was approved by the 
Ethics Committee of the Kangbuk Samsung Hospital. All 
of the study subjects provided informed consent prior to 
participation.
Intervention
The GD clinic provided individual psychotherapy (PT), 
pharmacotherapy, and group CBT. The patients simulta-
neously received distinct therapeutic alternatives, such as 
GA, if they chose to participate.
Individual PT was based on CBT and motivational 
enhancement therapy, and lasted for 15–20  min in the 
outpatient clinic. Regular follow-up was recommended, 
regardless of whether other types of treatment were 
utilized [16]. The duration of an individual PT session 
cannot be longer because the Korean National Health 
Insurance System pays one CBT fee irrespective of the 
experts’ work experience (approximately 25 USD for 
30 min of CBT with a psychiatrist) [17].
The patients received medication based on their symp-
toms and clinical presentation. The patients received 
anticraving drugs for cravings to gamble, and antide-
pressants to cope with anxiety or depressed mood. To 
compare the effect of each pharmacotherapy, the psy-
chotropic drugs were classified as anticraving agents 
(naltrexone, acamprosate) and antidepressants (selec-
tive serotonin reuptake inhibitors—escitalopram, par-
oxetine, sertraline; serotonin–norepinephrine reuptake 
inhibitors—venlafaxine, milnacipran; norepineph-
rine–dopamine reuptake inhibitors—bupropion). The 
‘no-pharmacotherapy’ group was not administered any 
major psychotropic prescription drug during the treat-
ment period. Augmented benzodiazepines (as needed) 
were permitted and not considered in the data analy-
sis. The patients whose main therapy was antipsychot-
ics or mood stabilizers were excluded from the analyses 
because we assumed that they had an additional major 
diagnosis.
The group CBT for GD was composed of weekly 2-h 
sessions, for 8 weeks [18, 19]. All of the group CBT ses-
sions were conducted by a single psychiatrist (Y.C. Shin) 
three or four times per year from 2004 to 2012, except 
for the two groups in 2006 (by S.W. Choi). The group 
CBT included conventional therapeutic elements from 
CBT, such as psychoeducation, cognitive restructuring, 
and decisional balance. Moreover, therapeutic skills from 
motivational enhancement and logotherapy, including 
problem solving in other areas of life and the meaning of 
gambling in life, were combined in the treatment. Addi-
tional details on the CBT are shown in Fig. 1.
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Measurements
Treatment maintenance duration was evaluated by chart 
review. If a patient did not visit the GD clinic (unless 
according to an agreement with a therapist), the patient 
was regarded as a dropout. For the participants who had 
not dropped out, the treatment maintenance duration 
was calculated from the first visit to the day of the last 
visit before the chart review.
The characteristics of the participants’ gambling 
behavior were also evaluated at the first visit. The GD 
patients had a tendency to distort or minimize their 
debt, due to their gambling behavior [20]. If there was 
a lack of consensus between a patient and an accom-
panied family member’s report, then we chose the 
higher value. The classification of main gambling type 
was based on the following question: “What type of 
gambling has most disturbed your life and resulted in 
the greatest loss of money?” We classified gambling 
according to structural game characteristics [21]. “Stra-
tegic gambling” was defined as gambling activities for 
which the outcome is believed to be the result of the 
players’ skill or analysis, such as Poker or Go-stop. 
“Nonstrategic gambling” was defined as the gambling 
activities for which the outcome is generally believed to 
be a result of random probability, such as slot machines, 
roulette, or lotteries [16].
To evaluate the severity of gambling, the Korean ver-
sion of the Gambling Symptom Assessment Scale 
(GSAS) was used [22]. Each item of the GSAS is scored 
on a 5-point scale from 0 (no symptoms) to 4 (extreme 
symptoms). The total score ranges from 0 to 48. The Beck 
Depression Inventory (BDI) and Beck Anxiety Inventory 
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Fig. 1 Eight‑session group CBT for GD
Page 4 of 8Choi et al. Ann Gen Psychiatry  (2016) 15:20 
(BAI) were administered to assess comorbid depressive 
and anxiety symptoms, respectively [23].
Statistical analysis
To compare the distribution and frequency of the cate-
gorical variables, Pearson’s Chi-square test was used. The 
differences of scale scores and other continuous variables 
according to intervention were analyzed with independ-
ent t tests and one-way analysis of variance (ANOVA). 
Analysis of covariance (ANCOVA) was conducted with 
BDI, GSAS, and age as the covariates to analyze the total 
treatment maintenance duration among the three groups 
and examine the main and interactive effects of other 
demographic variables. To analyze the independent fac-
tors that were associated with the follow-up duration, a 
generalized linear model was used to adjust each con-
founding factor. All the analyses were performed using 
PASW Statistics 17.0 software (SPSS Inc., Chicago, IL, 
USA), with the cut-off for statistical significance set at 
p < 0.05.
Results
Demographic and clinical characteristics of the 
participants
Of the 758 subjects, 717 participants (94.59 %) were male. 
The participants had a mean age of 39.60 ±  9.94  years. 
The mean age at the onset of GD was 29.84 ± 8.39 years. 
Of the subjects, 391 (51.58  %) had graduated college or 
university. More than half of the participants (61.6  %) 
had a full-time job for more than half of their adult life, 
and 157 participants (20.8 %) never had a job during their 
lifetime. Of the patients, 469 (61.87 %) were married.
All of the 758 patients had debt due to GD. Gambling 
debt at the first visit was 119,897 ±  360,259 US dollars 
(exchanged from Korean Won). The mean GSAS and 
K-SOGS scores were 15.56 and 16.27, respectively. The 
greatest amount of money that each participant had ever 
won at one time by gambling, a so-called ‘big win’ [24], 
was 166,471 ± 962,448 US dollars, on average. A total of 
150 subjects (19.7  %) gambled online. Of the gambling 
types, strategic gambling was most preferred (51.6  %), 
followed by nonstrategic gambling (17.4  %) and mixed 
(31.0 %). A considerable portion of the subjects (n = 555, 
72.9 %) had a psychiatric comorbidity. Depression (9.7 %) 
was the most prevalent comorbidity, followed by alcohol-
related disorders (8.5 %) and bipolar disorder (2.1 %).
Treatment maintenance duration and pharmacotherapy
The mean treatment maintenance duration was 
8.32  ±  16.21  months. Forty-eight patients (6.3  %) 
did not drop out, with a mean treatment length of 
36.43  ±  31.28  months. Of the subjects, 129 (17.01  %) 
continued to visit the GD clinic for longer than a year, 
with a follow-up duration of 26.47 ± 24.48 months.
The treatment duration was compared according to the 
accompanying pharmacotherapy. A total of 477 subjects 
(62.92  %) composed the no-pharmacotherapy group. The 
proportion of dropout was significantly lower among the 
patients who were treated with pharmacotherapy, despite 
their greater severity of symptoms (F =  8.88, p =  0.003). 
The treatment maintenance duration was longer in the 
pharmacotherapy group (t = 5.58, p < 0.001); however, this 
result had only marginal significance after adjusting for age, 
depression, and GD severity (F = 3.64, p = 0.057) (Table 1).
The patients who took medication were classified into 
either the antidepressant group (n = 104) or the anticrav-
ing agent group (n = 177). Nine subjects were prescribed 
acamprosate, with a mean dosage of 703.00 ± 260.32 mg/
day, and 168 subjects were prescribed naltrexone, with 
a mean dosage of 36.75 ±  16.62  mg/day. The follow-up 
duration was 10.37  ±  14.61  months for the anticraving 
agent group and 17.56  ±  26.99  months for the antide-
pressant group. The follow-up duration differed between 
the two pharmacotherapy groups (t = −2.51, p = 0.013), 
but this difference was not significant after adjusting for 
age, BDI, and GSAS (F = 1.83, p = 0.161) (Table 2).
A generalized linear model showed the factors that 
were associated with treatment duration in all GD 
patients. Sex, age, age of onset, religion, marital status, 
and other demographic factors were not associated with 
treatment duration. However, participation in group CBT 
and antidepressant prescriptions were related to longer 
treatment duration (Table 3).
Combined effect of pharmacotherapy and group CBT
We also compared the treatment maintenance dura-
tion according to the interventions. The mean number 
of months of follow-up differed across the interventions 
(F =  35.79, p  <  0.001). The patients who received indi-
vidual PT (n  =  409) displayed a significantly smaller 
number of follow-up months than did all the other 
intervention groups (3.39 ±  7.51 months), even accord-
ing to the post hoc analysis (p =  0.03 for the compari-
son with the anticraving agent group; p  <  0.001 for the 
comparison with the other groups). However, those who 
received combined group CBT and antidepressant treat-
ment for GD demonstrated the longest follow-up period 
(38.86  ±  41.77  months) compared with all the other 
intervention groups (p < 0.001) (Fig. 2).
Additionally, we classified the patients into the follow-
ing four groups regardless of the type of medication they 
were prescribed: (1) individual PT (n =  409), (2) group 
CBT (n =  68), (3) pharmacotherapy (n =  228), and (4) 
combined group CBT and pharmacotherapy (n  =  53). 
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There was a significant difference in follow-up duration 
among the four groups (F = 48.41, p < 0.001). This result 
was preserved after adjusting for confounding factors 
such as age, BDI, and GSAS (F = 27.41, p < 0.001). How-
ever, combined group CBT and pharmacotherapy 
(24.70 ± 28.37 months) was superior to pharmacotherapy 
Table 1 Clinical characteristics of subjects (n = 758)
BDI Beck Depression Inventory, BAI Beck Anxiety Inventory, GSAS Gambling Symptom Assessment Scale, CBT cognitive behavioral therapy, GA gamblers anonymous
a Fischer’s exact test (or Chi-square test): Data are shown as the number of patients (%), statistical value = Pearson’s Chi square
b Independent t test: Data are shown as mean ± standard deviation, statistical value = t
** p < 0.01
1 USD ≒ 1000 won
No-pharmacotherapy (n = 477) Pharmacotherapy (n = 281) Statistical value p
Demographic characteristics
 Sex (male %) 450 (94.5) 267 (95.0) 0.85a 0.388
 Age 40.40 ± 10.27 38.24 ± 9.23 2.98b 0.003**
 Age of onset 30.74 ± 8.92 28.29 ± 7.15 8.10b <0.001**
 With partner (or married) 307 (63.1) 166 (59.1) 2.11a 0.162
 Education (years) 14.14 ± 2.58 13.93 ± 2.54 1.06b 0.289
 Religion 196 (44.2) 127 (45.2) 0.91a 0.350
Gambling characteristics
 Type of main gambling
  Strategic 245 (51.4) 146 (52.0) 2.21a 0.332
  Nonstrategic 90 (18.9) 42 (14.9)
  Mixed 142 (29.8) 93 (33.1)
  Gambling debt at the first visit ($) 130,470 ± 434,212 102,872 ± 187,295 0.96b 0.338
  Big win ($) 250,692 ± 1,241,680 44,351 ± 128,800 1.77b 0.078
  BDI 10.82 ± 10.66 16.89 ± 11.07 −5.26b <0.001**
  BAI 16.75 ± 9.68 22.24 ± 9.96 −5.27b <0.001**
  GSAS 12.88 ± 9.59 19.01 ± 11.55 −5.36b <0.001**
 Intervention
  Group CBT 68 (14.3) 53 (18.9) 2.70a 0.102
  Participation in GA 106 (25.4) 80 (28.5) 3.13a 0.091
  Follow‑up duration (months) 5.53 ± 12.37 13.03 ± 20.35 −5.58 <0.001**
Table 2 Clinical characteristics according to pharmacotherapy
BDI Beck Depression Inventory, BAI Beck Anxiety Inventory, GSAS Gambling Symptom Assessment Scale, CBT cognitive behavioral therapy, GA gamblers anonymous
a Pearson’s Chi-square test: Data are shown as the number of patients (%), statistical value = Pearson’s Chi square











Sex (male %) 450 (94.5) 175 (98.9) 92 (91.1) 9.20a 0.010
Age 40.40 ± 10.27 37.45 ± 8.04 39.58 ± 10.86 5.73b 0.003**
Age of onset 30.74 ± 8.92 27.87 ± 6.19 29.00 ± 8.56 8.10b <0.001**
With partner (or married) 307 (63.1) 113 (64.8) 53 (51) 6.52a 0.038
BDI 10.82 ± 10.66 15.00 ± 10.23 20.67 ± 11.81 6.94b 0.002**
BAI 16.75 ± 9.68 20.09 ± 9.24 26.60 ± 10.00 9.72b <0.001**
GSAS 12.88 ± 9.59 20.07 ± 11.83 16.88 ± 10.77 3.01b 0.056
Group CBT 68 (14.3) 39 (22) 14 (13.6) 6.23a 0.044
Participation in GA 106 (25.4) 54 (34.4) 26 (27.4) 4.59a 0.101
Follow‑up duration (months) 5.53 ± 12.37 10.37 ± 14.61 17.56 ± 26.99 27.19 <0.001**
Page 6 of 8Choi et al. Ann Gen Psychiatry  (2016) 15:20 
only (10.32 ±  16.95  months, F =  26.16, p  <  0.001), but 
not superior to group CBT only in terms of the number 
of follow-up months (18.53 ± 23.39 months, F = 0.514, 
p = 0.416).
Discussion
The current data from 758 Korean GD patients showed 
that participation in group CBT and medication was 
associated with longer treatment duration without severe 
recurrence in an outpatient GD clinic. Antidepressants 
independently influenced longer maintenance of treat-
ment. Neither demographic factors nor the severity and 
characteristics of GD were associated with dropout.
To the best of our knowledge, this study is the first to 
compare treatment duration and dropout according to 
treatment modality in a clinical setting. GD is a biopsy-
chological disorder that may be attenuated if patients 
adhere to medication [25]. The current data suggest the 
importance of appropriate interventions, including com-
bined psychological and biological intervention [26]. 
Although previous researchers independently demon-
strated the effect of pharmacotherapy and group CBT on 
GD, the current study is the first to investigate the com-
bined effect on treatment adherence [27–29]. As a single 
psychiatrist gathered the current data over the course of 
10 years, the data are free from diversity in the practice 
and skill of the therapist.
The structure of medical service in South Korea should 
be considered in order to understand the limited influ-
ence of individual PT. This result is in line with the study 
that compared individual and group CBT [30]. Due to the 
low medical cost defined by the Korean National Medi-
cal Insurance System, Korean psychiatrists manage 28.7 
patients per day in the outpatient clinics of university 
hospitals [31]. Thus, ‘individual PT’ for approximately 
15–30 min in outpatient clinic did not enhance the treat-
ment adherence of GD patients. On the other hand, 
participation in group CBT for 16  h over the course of 
8 weeks, including family therapy during the last session, 
Table 3 Factors associated with  treatment maintenance 
duration
BDI Beck Depression Inventory, GSAS Gambling Symptom Assessment Scale, CBT 
cognitive behavioral therapy, GA gamblers anonymous
Generalized linear model, * p < 0.05
Parameter SE 95 % CI Hypothesis test




Female 5.1326 −6.855 13.264 0.390 0.532
Religion 1.5804 −1.528 4.667 0.986 0.321
Age of onset 0.1086 −.272 0.154 0.295 0.587
BDI 0.0817 −.136 0.184 0.087 0.768
GSAS total 0.0842 −.221 0.109 0.442 0.506
Group CBT 2.0324 10.724 18.691 52.364 <001*
Participation 
in GA
1.7992 −4.657 2.396 0.395 0.530
Anticraving 
agent
1.8385 −1.585 5.622 1.205 0.272
Antidepres‑
sant

































Fig. 2 Combined effect of pharmacotherapy and group CBT. All of the treatment groups received individual psychotherapy. Mean follow‑up 
months. *Significantly shorter than all other interventions (p < 0.001). **Significantly longer than all other interventions (p < 0.001)
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requires the family support that is necessary for success-
ful treatment. Participation in group CBT is also consid-
ered to provide psychological support from significant 
others [32]. We cautiously assumed that if individual PT 
was performed as intensively as group CBT, then the out-
comes of the treatment would be different. The current 
data do not suggest that group CBT is better than indi-
vidual PT, but show that intensive treatment with various 
modalities can enhance treatment adherence. Both group 
CBT and pharmacotherapy were superior to individ-
ual PT in terms of patients’ maintenance of therapeutic 
alliance.
The association between antidepressant prescription 
and a lower rate of dropout does not necessarily indicate 
that antidepressants might be more effective than ant-
icraving agents or other pharmacological interventions 
for GD patients. If we considered the severity of GD and 
depression, treatment duration did not differ according 
to the class of medication. The current data are in agree-
ment with previous research that found no significant 
difference in the outcome according to the use of anti-
depressants, anticraving agents, and mood stabilizers to 
manage GD [33]. Patients who are prescribed antidepres-
sants, such as an emotionally vulnerable group, might 
be more adherent to treatment than behaviorally condi-
tioned action gamblers [34]. Likewise, those with a mood 
disorder, or alcohol-dependent patients with depres-
sive symptoms, might have an increased willingness to 
receive treatment in a clinic.
This study was subject to several limitations. First, 
dropout does not necessarily indicate the termination of 
treatment. Although the Kangbuk Samsung Hospital has 
the largest GD outpatient clinic in South Korea, some 
patients may have visited a different clinic. Although the 
patients who were referred to GA were excluded in this 
study, some patients might have voluntarily registered for 
GA. Second, this study did not consider natural recov-
ery from addiction [35]. However, the traditional disease 
model of addiction regards addiction as progressive and 
irreversible; thus, recovery is difficult without continu-
ous treatment [36]. Third, 94.59  % of the participants 
were male, which may reduce the generalizability of the 
present results to female gambling disorder patients. 
Fourth, the data were derived from 10-year retrospec-
tive data; thus, the intervention was not accurately regu-
lated. Specifically, the type and dose of antidepressants 
were not controlled. Additionally, augmented benzodi-
azepines were permitted, but not controlled and consid-
ered in the data analysis. Furthermore, the GSAS was not 
measured regularly; thus, various outcomes could not 
be evaluated. Although remission is not considered due 
to the high recurrence rate and life-long course of GD, 
the regular measurement of treatment outcomes, such 
as GSAS, may aid in the assessment of the outcomes of 
each treatment. Given that the current research was not 
planned at the beginning of the study period, individual 
PT was not structured and objectively observed by other 
physicians. However, this is also a strength of the study, 
which showed 10 years of naturalistic data in a real clini-
cal setting.
Conclusions
This study is the first to examine the clinical character-
istics and interventions that affect increased treatment 
duration in GD patients. Group CBT and any type of 
medication were associated with a lower rate of drop-
out. Combined group CBT and antidepressants was 
the most effective intervention in maintaining the GD 
patients’ treatment. The current results suggest that mul-
tiple treatment approaches are needed to enhance the 
patients’ motivation and decrease the dropout rate.
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